A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Conference Paper

Full Text

Link to Item

Duke Authors

Armstrong, Andrew John

Cited Authors

Tran, B; Kouros-Mehr, H; Fermin, A; Horvath, L; Roncolato, F; Rettig, M; Dorff, T; Tagawa, ST; Subudhi, SK; Antonarakis, ES; Armstrong, AJ; Petrylak, DP; Fizazi, K; Salvati, ME; Scher, HI

Published Date

October 1, 2019

Published In

Annals of Oncology

Volume / Issue

30 /

Start / End Page

353 - 353

Published By

OXFORD UNIV PRESS

Pages

1

Electronic International Standard Serial Number (EISSN)

1569-8041

International Standard Serial Number (ISSN)

0923-7534

Conference Name

44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Conference Location

Barcelona, SPAIN

Conference Start Date

September 27, 2019

Conference End Date

October 1, 2019